What is ACET's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ACET?

P/E (TTM) is n/a and 52-week range is $5.55 to $17.44 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ACET figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ACET?

The company profile lists revenue (TTM) near $39M, net income (TTM) near $-3.60B, EPS (TTM) near $-13.02 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Adicet Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 9.3M shares outstanding, ISIN US0070022076 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Adicet Bio Inc

$ACET

Health Care · Biotechnology

IR Run Scenarios

$5.61

-2.26%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. The company is headquartered in Boston, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2018-01-26. The company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

Employees

102

Website

www.adicetbio.com/

IPO

2018-01-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)